Multivariate toxicity screening of liposomal formulations on a human buccal cell line

International Journal of Pharmaceutics

Volumn 330, Issue 1-2, 2007, Pages 14-22

  Smistad, Gro ^a   Jacobsen, Jette ^b   Sande, Sverre A ^a  

^a UNIVERSITY OF OSLO   (Norway)

^b UNIVERSITY OF COPENHAGEN   (Denmark)

Author keywords

Buccal cell line; Cellular toxicity; Liposomes; Multivariate data analysis

Indexed keywords

1,2 DIOLEOYL 3 TRIMETHYLAMMONIOPROPANE; DIACYLTRIMETHYLAMMONIUM PROPANE; DIMYRISTOYLPHOSPHATIDIC ACID; DIMYRISTOYLPHOSPHATIDYLCHOLINE; DIMYRISTOYLPHOSPHATIDYLSERINE; DIMYRISTOYLTRIMETHYLAMMONIUM PROPANE; DIOLEYLPHOSPHATIDYLSERINE; DIPALMITOYLPHOSPHATIDYLCHOLINE; DIPALMITOYLPHOSPHATIDYLSERINE; DIPALMITOYLTRIMETHYLAMMONIUM PROPANE; LIPOSOME; OCTADECYLAMINE; PHENAZINE METHOSULFATE; PHOSPHATIDIC ACID; PHOSPHATIDYLCHOLINE; PHOSPHATIDYLGLYCEROL; UNCLASSIFIED DRUG;

ARTICLE; CELL ASSAY; CELL LINE; CHEEK; CONTROLLED STUDY; CYTOTOXICITY; DRUG FORMULATION; EXPERIMENTAL DESIGN; HUMAN; HUMAN CELL; MULTIVARIATE ANALYSIS; PRIORITY JOURNAL; STATISTICAL ANALYSIS;

CELL LINE, TUMOR; CHEEK; DIMYRISTOYLPHOSPHATIDYLCHOLINE; DRUG DELIVERY SYSTEMS; HUMANS; LIPOSOMES; MULTIVARIATE ANALYSIS; PHOSPHATIDYLCHOLINES; PHOSPHATIDYLGLYCEROLS; SURFACE PROPERTIES;

EID: 33846241302     PISSN: 03785173     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.ijpharm.2006.08.044     Document Type: Article

References (37)

1. Berrocal M.C., Bujan J., Garcia-Honduvilla N., and Abeger A. Comparison of the effects of dimyristoyl and soya phosphatidylcholine liposomes on human fibroblasts. Drug Deliv. 7 (2000) 37-44
2. Birudaraj R., Mahalingam R., Li X., and Jasti B.R. Advances in buccal drug delivery. Crit. Rev. Ther. Drug Carr. Syst. 22 (2005) 295-330
3. Boulmedarat L., Bochot A., Lesieur S., and Fattal E. Evaluation of buccal methyl-β-cyclodextrin toxicity on human oral epithelial cell culture model. J. Pharm. Sci. 94 (2005) 1300-1309
4. Boulmedarat L., Piel G., Bochot A., Lesieur S., Delattre L., and Fattal E. Cyclodextrin-mediated drug release from liposomes dispersed within a bioadhesive gel. Pharm. Res. 22 (2005) 962-971
5. Burgalassi S., Panichi L., Saettone M.F., Jacobsen J., and Rassing M.R. Development and in vitro/in vivo testing of mucoadhesive buccal patches releasing benzydamine and lidocaine. Int. J. Pharm. 133 (1996) 1-7
6. Campbell P.I. Toxicity of some charged lipids in liposome preparations. Cytobios 37 (1983) 21-26
7. Cevc G. Phospholipid Handbook (1993), Dekker, New York
8. Eirheim H.U., Bundgaard C., and Nielsen H.M. Evaluation of different toxicity assays applied to proliferating cells and to stratified epithelium in relation to permeability enhancement with glycocholate. Toxicol. In Vitro 18 (2004) 649-657
9. Erjavec V., Pavlica Z., Sentjurc M., and Petelin M. In vivo study of liposomes as drug carriers to oral mucosa using EPR oximetry. Int. J. Pharm. 307 (2006) 1-8
10. Esbensen K.H., Gyout D., and Westad F. Multivariate Data Analysis-in Practice (2000), Camo ASA, Trondheim, Norway
11. Farshi F.S., Özer A.Y., Ercan M.T., and Hincal A.A. In vivo studies in the treatment of oral ulcers with liposomal dexamethasone sodium phosphate. J. Microencaps. 13 (1996) 537-544
12. Filion M.C., and Phillips N.C. Toxicity and immunomodulatory activity of liposomal vectors formulated with cationic lipids towards immune effector cells. Biochim. Biophys. Acta 1329 (1997) 345-356
13. Filion M.C., and Phillips N.C. Major limitations in the use of cationic liposomes for DNA delivery. Int. J. Pharm. 162 (1998) 159-170
14. Gandhi R.B., and Robinson J.R. Oral cavity as a site for bioadhesive drug delivery. Adv. Drug Deliv. Rev. 13 (1994) 43-74
15. Hao J., and Heng P.W.S. Buccal delivery systems. Drug Dev. Ind. Pharm. 29 (2003) 821-832
16. Harsanyi B.B., Hilchie J.C., and Mezei M. Liposomes as drug carriers for oral ulcers. J. Dent. Res. 65 (1986) 1133-1141
17. Jacobsen J., Bjerregaard S., and Pedersen M. Cyclodextrin inclusion complexes of antimycotics intended to act in the oral cavity-drug supersaturation, toxicity on TR146 cells and release from a delivery system. Eur. J. Pharm. Biopharm. 48 (1999) 217-224
18. Jacobsen J., Pedersen M., and Rassing M.R. TR146 cells as a model for human buccal epithelium. II. Optimisation and use of a cellular sensitivity MTS/PMS assay. Int. J. Pharm. 141 (1996) 217-225
19. Juliano R.L., Grant C.W.M., Barber K.R., and Kalp M.A. Mechanism of the selective toxicity of amphotericin B incorporated into liposomes. Mol. Pharmacol. 31 (1987) 1-11
20. Layton D., Luckenbach G.A., Andreesen R., and Munder P.G. The interaction of liposomes with cells: the relation of cell specific toxicity to lipid composition. Eur. J. Cancer 16 (1980) 1529-1538
21. Martens H., and Martens M. Modified Jack-knife estimation of parameter uncertainty in bilinear modelling by partial least square regression (PLSR). Food Qual. Pref. 11 (2000) 5-16
22. Martens H., and Næs T. Multivariate Calibration (1989), Wiley and Sons Ltd.
23. Mayhew E., Gotfredsen C., Schneider Y., and Trouet A. Interaction of liposomes with cultured cells: effect of serum. Biochem. Pharmacol. 29 (1980) 877-886
24. Mayhew E., Ito M., and Lazo R. Toxicity of non-drug-containing liposomes for cultured human cells. Exp. Cell Res. 171 (1987) 195-202
25. Mönkkönen J., and Heath T.D. The effects of liposome-encapsulated and free clodronate on the growth of macrophage-like cells in vitro: the role of calcium and iron. Calcif. Tissue Int. 53 (1993) 139-146
26. Olson F., Mayhew E., Maslow D., Rustum Y., and Szoka F. Characterization, toxicity and therapeutic efficacy of adriamycin encapsulated in liposomes. Eur. J. Cancer Clin. Oncol. 18 (1982) 167-176
27. Parnham M.J., and Wetzig H. Toxicity screening of liposomes. Chem. Phys. Lipids 64 (1993) 263-274
28. Pedersen M., Bjerregaard S., Jacobsen J., Larsen A.R., and Sorensen A.M. An econazole beta-cyclodextrin inclusion complex: an unusual dissolution rate, supersaturation, and biological efficacy example. Int. J. Pharm. 165 (1998) 57-68
29. Petelin M., Sentjurc M., Stolic Z., and Skaleric U. EPR study of mucoadhesive ointments for delivery of liposomes into the oral mucosa. Int. J. Pharm. 173 (1998) 193-202
30. Phillips N.C., Gagné L., Ivanoff N., and Riveau G. Influence of phospholipid composition on antibody responses to liposome encapsulated protein and peptide antigens. Vaccine 14 (1996) 898-904
31. Rathbone M.J., Drummond B.K., and Tucker I.G. The oral cavity as a site for systemic drug delivery. Adv. Drug Deliv. Rev. 13 (1994) 1-22
32. Rupniak T.H., Rowlatt C., Lane E.B., Steele J.G., Trejdosiewicz L.K., Laskiewicz B., Povey S., and Hill B.T. Characteristics of four new human cell lines derived from squamous cell carcinomas of the head and neck. J. Natl. Cancer Inst. 75 (1985) 621-635
33. Stensrud G., Mönkkönen J., and Karlsen J. Toxicity of gamma irradiated liposomes. 2. In vitro effects on cells in culture. Int. J. Pharm. 178 (1999) 47-53
34. Stensrud G., Smistad G., and Karlsen J. Effect of gamma irradiation on the stability of liposomes/phospholipids. I. Chemical stability. Drug Stability 1 (1996) 152-160
35. Sveinsson S.J., and Holbrook W.P. Oral mucosal adhesive ointment containing liposomal corticosteroid. Int. J. Pharm. 95 (1993) 105-109
36. Szoka F., Jacobson K., Derzko Z., and Papahadjopoulos D. Fluorescence studies on the mechanism of liposome-cell interactions in vitro. Biochim. Biophys. Acta 600 (1980) 1-18
37. Yang T.Z., Wang X.T., Yan X.Y., and Zhang Q. Phospholipid deformable vesicles for buccal delivery of insulin. Chem. Pharm. Bull. 50 (2002) 749-753